Literature DB >> 15372591

Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations.

Christopher G Goetz1, Werner Poewe, Olivier Rascol, Cristina Sampaio, Glenn T Stebbins, Carl Counsell, Nir Giladi, Robert G Holloway, Charity G Moore, Gregor K Wenning, Melvin D Yahr, Lisa Seidl.   

Abstract

The Movement Disorder Society Task Force for Rating Scales for Parkinson's disease (PD) prepared a critique of the Hoehn and Yahr scale (HY). Strengths of the HY scale include its wide utilization and acceptance. Progressively higher stages correlate with neuroimaging studies of dopaminergic loss, and high correlations exist between the HY scale and some standardized scales of motor impairment, disability, and quality of life. Weaknesses include the scale's mixing of impairment and disability and its non-linearity. Because the HY scale is weighted heavily toward postural instability as the primary index of disease severity, it does not capture completely impairments or disability from other motor features of PD and gives no information on nonmotor problems. Direct clinimetric testing of the HY scale has been very limited, but the scale fulfills at least some criteria for reliability and validity, especially for the midranges of the scale (Stages 2-4). Although a "modified HY scale" that includes 0.5 increments has been adopted widely, no clinimetric data are available on this adaptation. The Task Force recommends that: (1) the HY scale be used in its original form for demographic presentation of patient groups; (2) when the HY scale is used for group description, medians and ranges should be reported and analysis of changes should use nonparametric methods; (3) in research settings, the HY scale is useful primarily for defining inclusion/exclusion criteria; (4) to retain simplicity, clinicians should "rate what you see" and therefore incorporate comorbidities when assigning a HY stage; and (5) because of the wide usage of the modified HY scale with 0.5 increments, this adaptation warrants clinimetric testing. Without such testing, however, the original five-point scales should be maintained.

Entities:  

Mesh:

Year:  2004        PMID: 15372591     DOI: 10.1002/mds.20213

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  568 in total

1.  Clinical markers for identifying cholinergic deficits in Parkinson's disease.

Authors:  Martijn L T M Müller; Nicolaas I Bohnen; Vikas Kotagal; Peter J H Scott; Robert A Koeppe; Kirk A Frey; Roger L Albin
Journal:  Mov Disord       Date:  2014-11-12       Impact factor: 10.338

2.  Utility of the Mini-BESTest, BESTest, and BESTest sections for balance assessments in individuals with Parkinson disease.

Authors:  Abigail L Leddy; Beth E Crowner; Gammon M Earhart
Journal:  J Neurol Phys Ther       Date:  2011-06       Impact factor: 3.649

3.  Factors Associated With Ambulatory Activity in De Novo Parkinson Disease.

Authors:  Cory Christiansen; Charity Moore; Margaret Schenkman; Benzi Kluger; Wendy Kohrt; Anthony Delitto; Brian Berman; Deborah Hall; Deborah Josbeno; Cynthia Poon; Julie Robichaud; Toby Wellington; Samay Jain; Cynthia Comella; Daniel Corcos; Ed Melanson
Journal:  J Neurol Phys Ther       Date:  2017-04       Impact factor: 3.649

4.  Energy cost of spontaneous walking in Parkinson's disease patients.

Authors:  Martina A Maggioni; Arsenio Veicsteinas; Susanna Rampichini; Emiliano Cè; Raffaello Nemni; Giulio Riboldazzi; Giampiero Merati
Journal:  Neurol Sci       Date:  2011-11-01       Impact factor: 3.307

5.  Movement orientation switching with the eyes and lower limb in Parkinson disease.

Authors:  Corey A Lohnes; Gammon M Earhart
Journal:  Parkinsonism Relat Disord       Date:  2012-01-20       Impact factor: 4.891

Review 6.  Late-stage Parkinson disease.

Authors:  Miguel Coelho; Joaquim J Ferreira
Journal:  Nat Rev Neurol       Date:  2012-07-10       Impact factor: 42.937

7.  Striatal and Cortical β-Amyloidopathy and Cognition in Parkinson's Disease.

Authors:  Neha Shah; Kirk A Frey; Martijn L T M Müller; Myria Petrou; Vikas Kotagal; Robert A Koeppe; Peter J H Scott; Roger L Albin; Nicolaas I Bohnen
Journal:  Mov Disord       Date:  2015-09-18       Impact factor: 10.338

8.  Deficient supplementary motor area at rest: Neural basis of limb kinetic deficits in Parkinson's disease.

Authors:  Stefanie Kübel; Katharina Stegmayer; Tim Vanbellingen; Sebastian Walther; Stephan Bohlhalter
Journal:  Hum Brain Mapp       Date:  2018-05-02       Impact factor: 5.038

9.  Olfactory Dysfunction in Parkinson's Disease Patients with the LRRK2 G2385R Variant.

Authors:  Ming Cao; Zhu-Qin Gu; Yuan Li; Hui Zhang; Xiao-Juan Dan; Shan-Shan Cen; Da-Wei Li; Piu Chan
Journal:  Neurosci Bull       Date:  2016-10-03       Impact factor: 5.203

10.  Effects of Fatigue on Balance in Individuals With Parkinson Disease: Influence of Medication and Brain-Derived Neurotrophic Factor Genotype.

Authors:  Michael Baer; Bradley Klemetson; Diana Scott; Andrew S Murtishaw; James W Navalta; Jefferson W Kinney; Merrill R Landers
Journal:  J Neurol Phys Ther       Date:  2018-04       Impact factor: 3.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.